Summary of Public Health Interventions Against Falsified Medicines

Introduction to Falsified Medicines

• Falsified medicines pose risks to patient health and healthcare systems.
• WHO employs terms like SSFFC (Substandard/spurious/falsely labelled/falsified/counterfeit).

Objectives of the Review

• Overview of public health interventions against falsified medicines in LMIC.
• Focus on policies addressing drug quality.

Key Findings

General Observations

• Global sales of counterfeit medicines estimated at ~$75 billion (2010).
• 28.5% median prevalence of poor quality medicines in LMIC studies.

International Policies

• Need for global reporting systems and international collaboration.
• Pharmacovigilance systems necessary for detecting drug-related issues.

National Strategies

• Strong National Medicines Regulatory Authorities (NMRA) needed.
• Drug screening and certification as pivotal elements of regulation.

Local Interventions

• Healthcare professional training on medicine quality and pharmacological testing.
• Innovative technologies for drug analysis in low-resource settings.

Consumer Empowerment

• Mobile Authentication Services (MAS) enable drug verification at sale points.
• Increased consumer education on recognizing poor quality medicines.

Conclusion

• Multi-level intervention strategies can significantly reduce the prevalence of falsified medicines.